MicroTech's CGM system gains global approval, positioning for market expansion

MicroTech Medical's LinX Continuous Glucose Monitoring (CGM) System – the international brand name for AiDEX X – has recently received marketing approval in India for continuous glucose monitoring in adults. With its exceptional performance and reliability, the LinX system has not only been incorporated into the healthcare reimbursement systems of multiple European countries but has also achieved market access in several emerging markets across the Middle East, Asia-Pacific, and South America. This establishes a diversified and sustainable framework for the company's international operations.

The global CGM market has demonstrated robust growth in recent years. India, as a key representative of emerging markets, holds substantial potential. According to the IDF Diabetes Atlas 2025, approximately 89.83 million adults aged 20-79 in India have diabetes, representing a prevalence rate of 9.5%, ranking the country second globally in the number of people affected. India also faces the highest number of diabetes-related deaths worldwide. More critically, the prevalence of prediabetes is rising, and the disease is showing a significant trend toward affecting younger populations. This exposes major gaps in the prevention and management system, creating an urgent and substantial demand for digital and intelligent diabetes management solutions.

The approval of MicroTech Medical's LinX CGM System in India marks the company's successful entry into this strategically vital, high-growth market. This move will significantly expand MicroTech Medical's overseas market reach, laying a solid foundation for the scaled expansion and revenue growth of its international business.

Looking ahead, MicroTech Medical will continue to focus on the global advancement of diabetes monitoring, treatment, and management methodologies, persistently driving technological and product innovation in these fields.